Lilly Completes $1.4 Billion Acquisition of Point Biopharma
US drug manufacturer Eli Lilly has completed its acquisition of radiopharmaceutical company Point Biopharma for approximately $1.4 billion.
radiopharmaceutical products
Bayer and Bicycle in Cancer Collaboration
Bayer and UK biotech Bicycle Therapeutics have agreed to collaborate to develop and commercialize the latter’s radioconjugates for multiple oncology targets.
Ariceum and AmbioPharm in Peptide Partnership
Ariceum Therapeutics, a Berlin-headquartered private biotech developing radiopharmaceutical products for the diagnosis and systemic targeted certain hard-to-treat cancers, and AmbioPharm, a globally oriented US CDMO specialized in peptides, have agreed a strategic partnership in peptide conjugates.
